Anaplastic nephroblastomas express transketolase-like enzyme 1

Journal of Clinical Pathology

Volumn 62, Issue 5, 2009, Pages 460-463

  Wu, H T ^a,b   Allie, N ^a   Myer, L ^a   Govender, D ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; MONOCLONAL ANTIBODY; PARAFFIN; TRANSKETOLASE; TRANSKETOLASE LIKE ENZYME 1; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ARTICLE; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NEPHRECTOMY; NEPHROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TISSUE SECTION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; MALE; NEOADJUVANT THERAPY; NEPHRECTOMY; TRANSKETOLASE; TUMOR MARKERS, BIOLOGICAL; WILMS TUMOR;

EID: 66349094049     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2008.063966     Document Type: Article

References (33)

1. Coy JF, Dressler D, Wilde J, et al. Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab 2005;51:257-273 (Pubitemid 40895125)
2. Földi M, Stickeler E, Bau L, et al. Transketolase protein TKTL1 overexpression: a potential biomarker and therapeutic target in breast cancer. Oncol Rep 2007;17:841-845
3. Schultz H, Kähler D, Branscheid D, et al. TKTL1 is overexpressed in a large portion of non-small cell lung cancer specimens. Diagn Pathol 2008;3:35-40.
4. Zhang S,Yue JX, Yang JH, etal.Overexpression of transketolase proteinTKTL1 is associated withoccurrence andprogressionin nasopharyngeal carcinoma: apotential therapeutic target in nasopharyngeal carcinoma [abstract]. Cancer Biol Ther 2008;7:517-522
5. Schmidt M, Kammerer U, Segerer S, et al. Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. Eur J Obstet Gynecol Reprod Biol 2008;139:72-78
6. Staiger WI, Coy JF, Grobholz R, et al. Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. Oncol Rep 2006;16:657-661
7. Völker HU, Hagemann C, Coy J, et al. Expression of transketolase-like 1 and activation of Akt in grade IV glioblastomas compared with grades II and III astrocytic gliomas [abstract]. Am J Clin Pathol 2008;130:50-57
8. Kohrenhagen N, Voelker HU, Schmidt M, et al. Expression of transketolase-like 1 (TKTL1) and p-Akt correlates with the progression of cervical neoplasia. J Obstet Gynaecol Res 2008;34:293-300.
9. Krockenberger M, Honig A, Rieger L, et al. Transketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastases. Int J Gynecol Cancer 2007;17:101-106 (Pubitemid 46213977)
10. Langbein S, Frederiks WM, zur Hausen A, et al. Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer [abstract]. Int J Cancer 2008;122:2422-2428
11. Völker HU, Scheich M, Schmausser B, et al. Overexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomas. Eur Arch Otorhinolaryngol 2007;264:1431-1436 (Pubitemid 350112408)
12. Langbein S, Zerilli M, Zur Hausen A, et al. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 2006;94:578-585 (Pubitemid 43289763)
13. Zerilli M, Amato MC, Martorana A, et al. Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymphnode metastases [abstract]. Cancer 2008;113:936-944
14. Govender D. The pathology of nephroblastoma. Curr Diagn Pathol 2000;6:45-54. (Pubitemid 30447645)
15. Weirich A, Ludwig L, Graf N, et al. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity. Ann Oncol 2004;15:808-820 (Pubitemid 38714745)
16. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumor. Results from the first National Wilms Tumor Study. Cancer 1978;41:1937-1948
17. Faria P, Beckwith JB, Mishra K, et al. Focal versus diffuse anaplasia in Wilms tumor - new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. Am J Surg Pathol 1996;20:909-920 (Pubitemid 26250632)
18. Govender D, Harilal P, Hadley GP, et al. p53 protein expression in nephroblastomas: a predictor of poor prognosis. Br J Cancer 1998;77:314-318 (Pubitemid 28029549)
19. Camassei FD, Arancia G, Cianfriglia M, et al. Nephroblastoma: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells. Am J Clin Pathol 2002;117:484-490 (Pubitemid 34226087)
20. Safford SD, Goyeau D, Freemerman AJ, et al. Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases. Ann Surg Oncol 2003;10:136-143 (Pubitemid 40485933)
21. Wittmann S, Wunder C, Zirn B, et al. New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors. Genes Chromosomes Cancer 2008;47:386-395
22. Zirn B, Hartmann O, Samans B, et al. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. Int J Cancer 2006;118:1954-1962
23. Tretiakova M, Turkyilmaz M, Grushko T, et al. Topoisomerase II alpha in Wilms' tumour: gene alterations and immunoexpression. J Clin Pathol 2006;59:1272-1277 (Pubitemid 46048331)
24. Rae FK, Martinez G, Gillinder KR, et al. Analysis of complementary expression profiles following WT1 induction versus repression reveals the cholesterol/fatty acid synthetic pathways as a possible major target of WT1 [abstract]. Oncogene 2004;23:3067-3079 (Pubitemid 38648197)
25. Comin-Anduix B, Boren J, Martinez S, et al. The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study [abstract]. Eur J Biochem 2001;268:4177-4182 (Pubitemid 32862878)
26. Boros LG, Puigjaner J, Cascante M, et al. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res 1997;57:4242-4248 (Pubitemid 27413432)
27. Rais B, Comin B, Puigjaner J, et al. Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. FEBS Lett 1999;456:113-118 (Pubitemid 29339052)
28. Fröhlich E, Fink I, Wahl R. Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines. Invest New Drugs. Published Online First: 20 September 2008. doi:10.1007/s10637-008-9174-9178
29. Zhang S, Yang JH, Guo CK, et al. Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Lett 2007;253:108-114 (Pubitemid 46874727)
30. Hu LH, Yang JH, Zhang DT, et al. The TKTL1 gene influences total transketolase activity and cell proliferation in human colon cancer LoVo cells [abstract]. Anticancer Drugs 2007;18:427-433 (Pubitemid 46712406)
31. Freedland SJ, Mavropoulos J, Wang A, et al. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate 2008;68:11-19
32. Otto C, Kaemmerer U, Illert B, et al. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer 2008;8:122-133
33. Zhou W, Mukherjee P, Kiebish MA, et al. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab (Lond) 2007;4:5-19. (Pubitemid 46393945)